Effect of omalizumab on outcomes in patients with aspirin-exacerbated respiratory disease

被引:31
作者
Jean, Tiffany [1 ,2 ]
Eng, Victoria [1 ]
Sheikh, Javed [1 ]
Kaplan, Michael S. [1 ]
Goldberg, Bruce [1 ]
Yang, Su Jau [3 ]
Samant, Shefali [1 ]
机构
[1] Kaiser Permanente Los Angeles Med Ctr, Dept Allergy & Immunol, Los Angeles, CA USA
[2] Univ Calif Irvine, Dept Clin Immunol & Allergy, Med Ctr, Irvine, CA USA
[3] Kaiser Permanente, Dept Res & Evaluat, Pasadena, CA USA
关键词
DESENSITIZATION;
D O I
10.2500/aap.2019.40.4241
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: The current treatment for patients with aspirin-exacerbated respiratory disease (AERD) who have uncontrolled asthma or chronic rhinosinusitis is aspirin desensitization. For patients who are unable to undergo or do not benefit from aspirin desensitization, treatment with biologics is an option, although efficacy data for AERD is scarce. Objective: We reported a series of patients with AERD who were started on omalizumab and measured the outcomes to assess improvement. Methods: Adult patients with AERD who were initiated on omalizumab from January 2007 to January 2018 were included. We compared outcomes 6-12 months before initiating biologic therapy and during the last 6-12 months while they were on biologic therapy. Our study investigated the number of oral steroid courses, short-acting beta-agonists (SABA), antibiotics for sinusitis or pneumonia, emergency department visits, hospitalizations, pulmonary function tests, and changes in controller medications. Results: Twenty-nine patients were placed on omalizumab. Sixty-two percent demonstrated a reduction in the number of steroid courses (p = 0.0014) and number of SABA canisters used (p = 0.0005) during their last 12 months while on omalizumab. Eighty-six percent of the patients with AERD and on omalizumab demonstrated either a decrease in the number of steroid courses or number of SABA canisters used in the last year of the study. The patients with AERD and with concomitant immunoglobulin E (IgE) mediated respiratory disease showed a statistically significant reduction in the number of steroid courses and number of SABA canisters used while on omalizumab for 1 year (p = 0.002 and p = 0.005, respectively), whereas those without concomitant IgE-mediated respiratory disease did not have a substantial reduction in or SABA canisters used. Conclusion: Our case series reported that omalizumab could effectively be used as an adjunct treatment for AERD, but additional larger and longitudinal studies are needed to corroborate these findings.
引用
收藏
页码:316 / 320
页数:5
相关论文
共 15 条
[1]   Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease [J].
Berges-Gimeno, MP ;
Simon, RA ;
Stevenson, DD .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 111 (01) :180-186
[2]   Update on the Management of Aspirin-Exacerbated Respiratory Disease [J].
Buchheit, Kathleen M. ;
Laidlaw, Tanya M. .
ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, 2016, 8 (04) :298-304
[3]   High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects [J].
Busse, William ;
Spector, Sheldon ;
Rosen, Karin ;
Wang, Yan ;
Alpan, Oral .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 132 (02) :485-+
[4]   Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma [J].
Djukanovic, R ;
Wilson, SJ ;
Kraft, M ;
Jarjour, NN ;
Steel, M ;
Chung, KF ;
Bao, WB ;
Fowler-Taylor, A ;
Matthews, J ;
Busse, WW ;
Holgate, ST ;
Fahy, JV .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 170 (06) :583-593
[5]   Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis [J].
Dursun, Adile Berna ;
Woessner, Katharine A. ;
Simon, Ronald A. ;
Karasoy, Durdu ;
Stevenson, Donald D. .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2008, 100 (05) :420-425
[6]   Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma [J].
Gevaert, Philippe ;
Calus, Lien ;
Van Zele, Thibaut ;
Blomme, Katrien ;
De Ruyck, Natalie ;
Bauters, Wouter ;
Hellings, Peter ;
Brusselle, Guy ;
De Bacquer, Dirk ;
van Cauwenberge, Paul ;
Bachert, Claus .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 131 (01) :110-U166
[7]   Omalizumab reduces cysteinyl leukotriene and 9α,11β-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease [J].
Hayashi, Hiroaki ;
Mitsui, Chihiro ;
Nakatani, Eiji ;
Fukutomi, Yuma ;
Kajiwara, Keiichi ;
Watai, Kentaro ;
Sekiya, Kiyoshi ;
Tsuburai, Takahiro ;
Akiyama, Kazuo ;
Hasegawa, Yoshinori ;
Taniguchi, Masami .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (05) :1585-1587
[8]   Clinical updates in aspirin-exacerbated respiratory disease [J].
Laidlaw, Tanya M. .
ALLERGY AND ASTHMA PROCEEDINGS, 2019, 40 (01) :4-6
[9]   Omalizumab can inhibit respiratory reaction during aspirin desensitization [J].
Lang, David M. ;
Aronica, Mark A. ;
Maierson, Elizabeth S. ;
Wang, Xiao-Feng ;
Vasas, Dorothy C. ;
Hazen, Stanley L. .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (01) :98-104
[10]  
MacGlashan DW, 1997, J IMMUNOL, V158, P1438